#ESC26: Trial failure clouds future of AstraZeneca’s heart disease gene silencer
Data ReadoutnegativeWainuaNegative
AI Analysis
Summary
AstraZeneca and Ionis Pharmaceuticals' Wainua gene silencer failed a high-profile trial for heart disease, with the failure attributed to concurrent use of a Pfizer drug for the same indication in trial patients.
Clinical Trial Data
Primary Endpoint
Not Met
Outcome Details
High-profile study failed; patients in trial were also taking a Pfizer drug for the same condition
Importance:8/10
Sentiment:
-0.80
Phase 3trial failuregene silencercardiovascularpartnership
Read the original article
Published by Endpoints News on August 28, 2026 9:10 AM